04-07-2022, 12:11 AM
Nuvaxovid incites “broad antibody responses” to both the original Covid-19 variant, to Omicron, and to “other circulating variants” as well. And just in case anyone missed the point, Novavax stated straight out that it “will be ready to supply Omicron-based vaccine this fall in accordance with FDA Advisory Committee recommendation” — and noted that it told VRBPAC so when it participated in the same meeting that resulted in the 19-2 recommendation to focus on Omicron going forward.
https://www.tipranks.com/news/article/sc...-for-that/
https://www.tipranks.com/news/article/sc...-for-that/